Peptides
116 profiles, grouped by area of study. A few related compounds that are not peptides are included and labelled. Search by name or filter by FDA status.
Showing 116 profiles
Metabolic and weight
5-Amino-1MQ
Also called 5-Amino-1-methylquinolinium
A small synthetic compound, not a peptide, that blocks the enzyme NNMT. A 2018 study found that obese mice given it lost weight; no human studies are reported.
Albiglutide
Also called Tanzeum
A GLP-1 receptor agonist made by fusing GLP-1 analogue peptides to human albumin. FDA approved it as Tanzeum in 2014, and Drugs@FDA lists it as discontinued.
Amycretin
Also called Zenagamtide
An experimental Novo Nordisk GLP-1 and amylin receptor agonist, now named zenagamtide and in registered Phase 3 trials. It is not FDA-approved.
AOD-9604
Also called AOD-9604 acetate
A synthetic fragment of human growth hormone that is not FDA-approved. FDA reports that its developer ended work on it for obesity after a trial found no significant weight loss.
Avexitide
A synthetic GLP-1 receptor-blocking peptide, exendin (9-39), in development for low blood sugar after bariatric surgery. No FDA approval is reported in the cited sources.
Cagrilintide
Also called AM833, CagriSema
An experimental long-acting amylin analogue from Novo Nordisk, studied alone and combined with semaglutide as CagriSema. FDA says it is not an approved drug and cannot be used in compounding.
Cotadutide
A synthetic dual GLP-1 and glucagon receptor agonist studied in type 2 diabetes, obesity and liver and kidney disease. No FDA approval is reported in the cited sources.
Dasiglucagon
Also called Zegalogue
A synthetic glucagon analogue approved by FDA in 2021 as Zegalogue for severe low blood sugar in people with diabetes. Drugs@FDA now lists both Zegalogue products as discontinued.
Dulaglutide
Also called Trulicity
A GLP-1 receptor agonist approved by FDA as Trulicity for blood-sugar control in type 2 diabetes and to lower cardiovascular risk in certain adults with type 2 diabetes.
Efpeglenatide
Also called HM11260C
A GLP-1 receptor agonist made by joining an exendin-4 analogue to an antibody fragment. A 4,076-person trial found fewer cardiovascular events than placebo; no FDA approval is reported.
Eloralintide
A synthetic amylin receptor agonist peptide in development for obesity. No FDA approval is reported in the cited sources.
Exenatide
Also called Byetta, Bydureon
A GLP-1 receptor agonist first approved by FDA as Byetta in 2005 to improve blood-sugar control in adults with type 2 diabetes.
Glucagon
Also called Gvoke VialDx, Gvoke, Baqsimi
A peptide hormone that raises blood sugar, FDA-approved since 1960. The cited label covers Gvoke for severe low blood sugar and Gvoke VialDx as a diagnostic aid.
Insulin glargine-aldy
Also called Langlara
A long-acting insulin glargine product licensed by FDA as Langlara in April 2026 to improve blood-sugar control in adults and children with diabetes.
Liraglutide
Also called Saxenda, Victoza
A GLP-1 receptor agonist approved by FDA as Victoza and Saxenda, with approved generic versions. Large randomized trials support its weight-management and cardiovascular evidence.
Lixisenatide
Also called Soliqua 100/33, Adlyxin
A GLP-1 receptor agonist approved by FDA as Adlyxin, and in combination with insulin glargine as Soliqua 100/33, to improve blood-sugar control in adults with type 2 diabetes.
Maridebart cafraglutide
Also called MariTide, AMG 133
An experimental Amgen antibody-peptide conjugate, also called MariTide, that blocks the GIP receptor and activates the GLP-1 receptor. It is in Phase 3 trials and not FDA-approved.
Mazdutide
Also called IBI362, LY3305677
A June 2025 Suzhou Industrial Park regulator report describes Chinese approval of mazdutide injection for long-term weight management in adults with obesity or overweight. A December 2025 Suzhou government report describes approved diabetes and weight-management indications in China.
Metreleptin
Also called Myalept
A recombinant form of the hormone leptin, a 147-amino-acid protein, not a peptide, approved by FDA in 2014 as Myalept for complications of leptin deficiency in generalized lipodystrophy.
MOTS-c
Also called MOTS-C, Mitochondrial open reading frame of the 12S rRNA-c
A 16-amino-acid mitochondrial peptide that is not FDA-approved. FDA’s 2026 review found no studies of MOTS-c in people.
Orforglipron
Also called Foundayo
A small-molecule GLP-1 receptor agonist, not a peptide, approved by FDA in April 2026 as Foundayo for weight reduction in adults with obesity or overweight with a related condition.
Petrelintide
Also called ZP8396
An experimental amylin analogue from Zealand Pharma and Roche, in Phase 3 trials. It is not FDA-approved.
Pramlintide
Also called SymlinPen, Symlin
An amylin analogue approved by FDA as Symlin, an add-on for people with type 1 or type 2 diabetes who use mealtime insulin.
Retatrutide
Also called LY3437943
An experimental GIP, GLP-1 and glucagon receptor agonist from Eli Lilly. FDA says it is not an approved drug and cannot be used in compounding.
Semaglutide
Also called Wegovy, Ozempic, Rybelsus
A GLP-1 receptor agonist approved by FDA as Ozempic, Rybelsus and Wegovy. Its approved uses rest on large randomized trials described in the label.
Setmelanotide
Also called Imcivree
An MC4 receptor agonist approved by FDA as Imcivree for acquired hypothalamic obesity, Bardet-Biedl syndrome and certain genetic deficiencies, not for general obesity.
SLU-PP-332
A small synthetic compound, not a peptide, that activates estrogen-related receptors and acted like exercise in mice. No human studies and no FDA approval are reported.
Survodutide
Also called BI 456906
An experimental glucagon and GLP-1 receptor dual agonist from Boehringer Ingelheim, studied in obesity and fatty liver disease. It is not FDA-approved.
Tesamorelin
Also called Egrifta
A growth hormone-releasing factor analogue approved by FDA as Egrifta to reduce excess abdominal fat in adults with HIV and lipodystrophy.
Tesofensine
Also called NS2330
A small synthetic drug, not a peptide, that blocks the reuptake of noradrenaline, dopamine and serotonin. It was studied in phase 2 trials for obesity and Parkinson disease, and no FDA approval is reported.
Tirzepatide
Also called Zepbound, Mounjaro
A GIP and GLP-1 receptor agonist approved by FDA as Mounjaro and Zepbound. In August 2026 FDA added a cardiovascular risk-reduction indication for Mounjaro.
VK2735
An experimental GLP-1 and GIP receptor dual agonist studied for weight management. In a 13-week phase 2 trial, average weight loss was 9.1% to 14.7%; no FDA approval is reported.
Heart and blood vessels
Albiglutide
Also called Tanzeum
A GLP-1 receptor agonist made by fusing GLP-1 analogue peptides to human albumin. FDA approved it as Tanzeum in 2014, and Drugs@FDA lists it as discontinued.
Bivalirudin
Also called Angiomax
A synthetic 20-amino-acid direct thrombin inhibitor approved by FDA, first as Angiomax, as an anticoagulant in patients undergoing percutaneous coronary intervention.
Dulaglutide
Also called Trulicity
A GLP-1 receptor agonist approved by FDA as Trulicity for blood-sugar control in type 2 diabetes and to lower cardiovascular risk in certain adults with type 2 diabetes.
Efpeglenatide
Also called HM11260C
A GLP-1 receptor agonist made by joining an exendin-4 analogue to an antibody fragment. A 4,076-person trial found fewer cardiovascular events than placebo; no FDA approval is reported.
Eptifibatide
Also called Integrilin
A synthetic cyclic heptapeptide platelet inhibitor approved by FDA, first as Integrilin, for acute coronary syndrome and for patients undergoing percutaneous coronary intervention.
Nesiritide
Also called Natrecor
A recombinant form of B-type natriuretic peptide, formerly FDA-approved as Natrecor for acute heart failure. FDA withdrew the approval in 2020 after it was no longer marketed.
Semaglutide
Also called Wegovy, Ozempic, Rybelsus
A GLP-1 receptor agonist approved by FDA as Ozempic, Rybelsus and Wegovy. Its approved uses rest on large randomized trials described in the label.
Vasopressin
Also called Vasostrict
A synthetic version of the peptide hormone arginine vasopressin, approved by FDA as Vasostrict to raise blood pressure in adults with vasodilatory shock.
Liver
Efinopegdutide
Also called HM12525A, JNJ-64565111
An experimental GLP-1 and glucagon receptor agonist studied for fatty liver disease. In a 24-week trial it reduced liver fat more than semaglutide; no FDA approval is reported.
Pemvidutide
Also called ALT-801
An experimental Altimmune glucagon and GLP-1 receptor agonist studied in the liver disease MASH. It is not FDA-approved.
Semaglutide
Also called Wegovy, Ozempic, Rybelsus
A GLP-1 receptor agonist approved by FDA as Ozempic, Rybelsus and Wegovy. Its approved uses rest on large randomized trials described in the label.
Survodutide
Also called BI 456906
An experimental glucagon and GLP-1 receptor dual agonist from Boehringer Ingelheim, studied in obesity and fatty liver disease. It is not FDA-approved.
Terlipressin
Also called Terlivaz
A synthetic vasopressin analogue approved by FDA as Terlivaz to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.
Hormones
Calcitonin salmon
Also called Miacalcin, Salmon calcitonin
A synthetic salmon calcitonin approved by FDA as Miacalcin for Paget’s disease of bone, high blood calcium and postmenopausal osteoporosis when other treatments are not suitable.
Cetrorelix
Also called Cetrotide
A synthetic GnRH antagonist decapeptide approved by FDA as Cetrotide to prevent premature LH surges in women undergoing controlled ovarian stimulation.
CJC-1295
Also called CJC-1295 DAC
A synthetic GHRH analogue that is not FDA-approved. FDA treats CJC-1295 and CJC-1295 with DAC as distinct substances and found only small, short studies in healthy adults.
Desmopressin
Also called DDAVP
A synthetic vasopressin analogue approved by FDA as DDAVP for central diabetes insipidus and primary bedwetting in children.
Etelcalcetide
Also called Parsabiv
A synthetic peptide calcium-sensing receptor agonist approved by FDA as Parsabiv for secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis.
Ganirelix
Also called Ganirelix acetate
A synthetic GnRH antagonist decapeptide approved by FDA to prevent premature LH surges in women undergoing controlled ovarian hyperstimulation.
GHRP-2
Also called Pralmorelin, Growth hormone-releasing peptide 2
A synthetic six-amino-acid growth hormone secretagogue, also called pralmorelin, that FDA lists among compounding substances that may present significant safety risks.
GHRP-6
Also called Growth hormone-releasing peptide 6
A synthetic six-amino-acid growth hormone secretagogue that FDA lists among compounding substances that may present significant safety risks.
Gonadorelin
Also called Factrel, Lutrepulse, Gonadorelin acetate, Gonadorelin hydrochloride
The synthetic form of gonadotropin-releasing hormone. FDA approved it as Factrel in 1982 and Lutrepulse in 1989, and Drugs@FDA lists both as discontinued.
Goserelin
Also called Zoladex
A synthetic GnRH analogue approved by FDA as Zoladex for prostate cancer, advanced breast cancer in pre- and perimenopausal women, endometriosis and endometrial thinning.
Hexarelin
Also called Examorelin
A synthetic six-amino-acid growth hormone secretagogue, also called examorelin, studied in small hormone studies in healthy volunteers. No FDA approval is reported in the cited sources.
Histrelin
Also called Supprelin LA
A synthetic GnRH analogue approved by FDA as Supprelin LA for children with central precocious puberty.
IGF-1 LR3
Also called Long R3 IGF-I, Long-(Arg3) insulin-like growth factor-I
An engineered, 83-amino-acid form of the growth factor IGF-1, a protein, not a peptide, made as a laboratory research tool. No human studies and no FDA approval are reported.
Ipamorelin
Also called Ipamorelin acetate
A synthetic five-amino-acid peptide that stimulates growth hormone release and is not FDA-approved. FDA’s 2024 review found one small randomized human trial, which showed no significant benefit.
Kisspeptin-10
A ten-amino-acid kisspeptin fragment that is not FDA-approved. FDA’s 2024 evaluation found only small, short human studies and insufficient evidence of effectiveness.
Lanreotide
Also called Lanreotide acetate, Somatuline Depot
A somatostatin analogue first approved by FDA as Somatuline Depot in 2007. The cited label covers acromegaly, certain neuroendocrine tumors and carcinoid syndrome.
Mecasermin
Also called Increlex
Recombinant human IGF-1, a 70-amino-acid protein, not a peptide, approved by FDA in 2005 as Increlex to treat growth failure in children with severe primary IGF-1 deficiency.
MK-677
Also called Ibutamoren, Ibutamoren mesylate, MK-0677
A small synthetic compound, not a peptide, also called ibutamoren, that prompts growth hormone release. FDA lists it among compounding substances that may present significant safety risks, citing congestive heart failure.
Nafarelin
Also called Synarel
A synthetic GnRH analogue approved by FDA as Synarel for central precocious puberty in children and for endometriosis in adult women.
Octreotide
Also called Octreotide acetate, Sandostatin
A somatostatin analogue first approved by FDA as Sandostatin in 1988, used for acromegaly and for diarrhea and flushing caused by certain hormone-secreting tumors.
Oxytocin
Also called Pitocin
A synthetic version of the pituitary hormone oxytocin, approved by FDA as Pitocin to start or strengthen labor contractions for medical reasons and to control bleeding after birth.
Palopegteriparatide
Also called Yorvipath
A long-acting prodrug of teriparatide (PTH 1-34) approved by FDA as Yorvipath for the treatment of hypoparathyroidism in adults.
Pasireotide
Also called Signifor
A synthetic cyclohexapeptide somatostatin analogue approved by FDA as Signifor for adults with Cushing’s disease for whom pituitary surgery is not an option or has not worked.
Sermorelin
Also called Geref
A synthetic 29-amino-acid fragment of growth hormone-releasing hormone, formerly FDA-approved as Geref. FDA withdrew Geref’s approvals in 2009 at the maker’s request and later found it was not withdrawn for safety or effectiveness reasons.
Triptorelin
Also called Trelstar
A synthetic GnRH agonist approved by FDA as Trelstar for the treatment of advanced prostate cancer.
Bone and growth
Abaloparatide
Also called Tymlos
A PTHrP analogue approved by FDA as Tymlos for postmenopausal women with osteoporosis at high risk of fracture and to increase bone density in men with osteoporosis.
Calcitonin salmon
Also called Miacalcin, Salmon calcitonin
A synthetic salmon calcitonin approved by FDA as Miacalcin for Paget’s disease of bone, high blood calcium and postmenopausal osteoporosis when other treatments are not suitable.
Etelcalcetide
Also called Parsabiv
A synthetic peptide calcium-sensing receptor agonist approved by FDA as Parsabiv for secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis.
Mecasermin
Also called Increlex
Recombinant human IGF-1, a 70-amino-acid protein, not a peptide, approved by FDA in 2005 as Increlex to treat growth failure in children with severe primary IGF-1 deficiency.
MOTS-c
Also called MOTS-C, Mitochondrial open reading frame of the 12S rRNA-c
A 16-amino-acid mitochondrial peptide that is not FDA-approved. FDA’s 2026 review found no studies of MOTS-c in people.
Palopegteriparatide
Also called Yorvipath
A long-acting prodrug of teriparatide (PTH 1-34) approved by FDA as Yorvipath for the treatment of hypoparathyroidism in adults.
Teriparatide
Also called Forteo
A parathyroid hormone analogue first approved by FDA as Forteo in 2002 for osteoporosis at high risk of fracture.
Vosoritide
Also called Voxzogo
A C-type natriuretic peptide analogue approved by FDA as Voxzogo, under accelerated approval, to increase linear growth in children with achondroplasia whose growth plates are open.
Gut and digestion
Apraglutide
A long-acting synthetic GLP-2 analogue in development for short bowel syndrome with intestinal failure. No FDA approval is reported in the cited sources.
BPC-157
Also called Body protection compound 157, Bepecin, PL 14736
A 15-amino-acid research peptide that is not FDA-approved. FDA’s 2026 review found only a few small, short human studies.
Glepaglutide
A long-acting synthetic GLP-2 analogue in development for short bowel syndrome with intestinal failure. No FDA approval is reported in the cited sources.
Ipamorelin
Also called Ipamorelin acetate
A synthetic five-amino-acid peptide that stimulates growth hormone release and is not FDA-approved. FDA’s 2024 review found one small randomized human trial, which showed no significant benefit.
Larazotide
Also called Larazotide acetate
A synthetic eight-amino-acid peptide studied for celiac disease. A randomized trial of 342 adults had mixed results, and no FDA approval is reported in the cited sources.
Linaclotide
Also called Linzess
A guanylate cyclase-C agonist approved by FDA as Linzess for irritable bowel syndrome with constipation and chronic constipation in adults, and for certain uses in children.
Plecanatide
Also called Trulance
A guanylate cyclase-C agonist approved by FDA as Trulance for chronic idiopathic constipation and irritable bowel syndrome with constipation in adults.
Secretin
Also called ChiRhoStim, Human secretin
A synthetic version of the human gut hormone secretin, approved by FDA as ChiRhoStim to help diagnose pancreatic problems and gastrin-producing tumors and to assist during ERCP.
Teduglutide
Also called Gattex
A GLP-2 analogue approved by FDA as Gattex for adults and children 1 year and older with short bowel syndrome who depend on parenteral support.
Brain, nerves and sleep
Cerebrolysin
A mixture of small peptides and amino acids from pig brain, used for stroke in several countries. A 2023 Cochrane review found it probably does not reduce deaths, and no FDA approval is reported.
Cibinetide
Also called ARA 290
A synthetic 11-amino-acid peptide, also called ARA 290, studied in small trials for nerve damage in sarcoidosis. No FDA approval is reported in the cited sources.
Dihexa
Also called Dihexa acetate, PNB-0408
A lab-made, stabilized fragment of the hormone angiotensin IV, designed as a possible dementia drug and tested in rats. FDA has identified no human exposure data, and no FDA approval is reported.
Emideltide
Also called DSIP, Delta sleep-inducing peptide
A nine-amino-acid peptide, also called DSIP, that is not FDA-approved. FDA’s 2026 review found its human studies small and inconclusive.
Epitalon
Also called AEDG, Epithalon, Ala-Glu-Asp-Gly
A synthetic four-amino-acid peptide that is not FDA-approved. FDA’s 2026 review found only a few small human reports and no studies in people with insomnia.
Glatiramer acetate
Also called Copaxone
A mixture of synthetic polypeptides made from four amino acids, not a single peptide. FDA approved it as Copaxone in 1996 for relapsing forms of multiple sclerosis.
Humanin
A 24-amino-acid peptide identified in 2001 as protecting nerve cells from Alzheimer disease-related damage in the laboratory. No human studies and no FDA approval are reported.
Oxytocin
Also called Pitocin
A synthetic version of the pituitary hormone oxytocin, approved by FDA as Pitocin to start or strengthen labor contractions for medical reasons and to control bleeding after birth.
Selank
Also called Selank acetate
A synthetic seven-amino-acid peptide that FDA lists among withdrawn compounding nominations with possible safety risks. FDA states that it lacks important information on its safety in people.
Semax
A synthetic seven-amino-acid peptide that is not FDA-approved in the United States. FDA’s 2026 review found only small, incompletely reported human studies.
Tesofensine
Also called NS2330
A small synthetic drug, not a peptide, that blocks the reuptake of noradrenaline, dopamine and serotonin. It was studied in phase 2 trials for obesity and Parkinson disease, and no FDA approval is reported.
Trofinetide
Also called Daybue
A synthetic compound built from three amino-acid units, approved by FDA as Daybue for Rett syndrome in adults and children 2 years and older.
Ziconotide
Also called Prialt
An N-type calcium channel blocker approved by FDA as Prialt for severe chronic pain in certain adults who cannot tolerate or did not respond to other treatments.
Skin
Afamelanotide
Also called Scenesse
A melanocortin receptor agonist approved by FDA as Scenesse to increase pain-free light exposure in adults with erythropoietic protoporphyria.
Daptomycin
Also called Cubicin, Cubicin RF
A cyclic lipopeptide antibiotic approved by FDA as Cubicin and Cubicin RF for complicated skin infections and Staphylococcus aureus bloodstream infections.
Difelikefalin
Also called Korsuva
A synthetic peptide kappa opioid receptor agonist approved by FDA as Korsuva for moderate-to-severe itching from chronic kidney disease in adults on hemodialysis.
GHK-Cu
Also called Copper tripeptide-1, GHK copper
A copper-binding peptide that FDA lists, except in injected forms, as under evaluation for pharmacy compounding. None of the sources reviewed reports an FDA approval.
Melanotan II
A synthetic cyclic seven-unit peptide that FDA lists among compounding substances that may present significant safety risks, citing case reports of serious adverse events.
Sexual and reproductive health
Bremelanotide
Also called Vyleesi, PT-141
A melanocortin receptor agonist approved by FDA as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Cetrorelix
Also called Cetrotide
A synthetic GnRH antagonist decapeptide approved by FDA as Cetrotide to prevent premature LH surges in women undergoing controlled ovarian stimulation.
Ganirelix
Also called Ganirelix acetate
A synthetic GnRH antagonist decapeptide approved by FDA to prevent premature LH surges in women undergoing controlled ovarian hyperstimulation.
Gonadorelin
Also called Factrel, Lutrepulse, Gonadorelin acetate, Gonadorelin hydrochloride
The synthetic form of gonadotropin-releasing hormone. FDA approved it as Factrel in 1982 and Lutrepulse in 1989, and Drugs@FDA lists both as discontinued.
Goserelin
Also called Zoladex
A synthetic GnRH analogue approved by FDA as Zoladex for prostate cancer, advanced breast cancer in pre- and perimenopausal women, endometriosis and endometrial thinning.
Kisspeptin-10
A ten-amino-acid kisspeptin fragment that is not FDA-approved. FDA’s 2024 evaluation found only small, short human studies and insufficient evidence of effectiveness.
Leuprolide
Also called Leuprolide acetate, Lupron, Eligard, Vobrig
A GnRH agonist FDA-approved since 1985 under several names. The cited Eligard label covers advanced prostate cancer; FDA approved Vobrig for central precocious puberty in August 2026.
Nafarelin
Also called Synarel
A synthetic GnRH analogue approved by FDA as Synarel for central precocious puberty in children and for endometriosis in adult women.
Tissue repair and wound healing
BPC-157
Also called Body protection compound 157, Bepecin, PL 14736
A 15-amino-acid research peptide that is not FDA-approved. FDA’s 2026 review found only a few small, short human studies.
FOXO4-DRI
A lab-designed peptide that makes ageing (senescent) cells die by blocking FOXO4 from holding p53. It restored some functions in old mice; no human studies and no FDA approval are reported.
GHK-Cu
Also called Copper tripeptide-1, GHK copper
A copper-binding peptide that FDA lists, except in injected forms, as under evaluation for pharmacy compounding. None of the sources reviewed reports an FDA approval.
KPV
Also called Lys-Pro-Val
A three-amino-acid peptide that is not FDA-approved. FDA’s 2026 review found no studies of KPV in people.
TB-500
Also called N-terminal acetylated 17-23 fragment of thymosin beta-4
A synthetic seven-amino-acid fragment of thymosin beta-4 that is not FDA-approved. FDA’s 2026 review found no studies of TB-500 in people.
Inflammation and immune
Glatiramer acetate
Also called Copaxone
A mixture of synthetic polypeptides made from four amino acids, not a single peptide. FDA approved it as Copaxone in 1996 for relapsing forms of multiple sclerosis.
Icatibant
Also called Firazyr
A synthetic decapeptide bradykinin B2 receptor blocker approved by FDA as Firazyr for acute attacks of hereditary angioedema in adults.
KPV
Also called Lys-Pro-Val
A three-amino-acid peptide that is not FDA-approved. FDA’s 2026 review found no studies of KPV in people.
LL-37
Also called Cathelicidin LL-37, Ropocamptide, LL37
A 37-amino-acid human cathelicidin peptide, also called ropocamptide, tested in small trials in chronic ulcers. FDA lists it among compounding substances that may present significant safety risks.
Pegcetacoplan
Also called Empaveli, Syfovre
A PEG-linked complement C3-blocking peptide approved by FDA as Empaveli for paroxysmal nocturnal hemoglobinuria and two complement-driven kidney diseases, and also sold as Syfovre.
Thymopentin
Also called Timunox
A synthetic five-amino-acid fragment of thymopoietin, studied as an immune modulator. Randomized trials in the 1990s had mixed results, and no FDA approval is reported.
Thymosin alpha-1
Also called Thymalfasin
A 28-amino-acid thymus peptide that is not FDA-approved. FDA’s 2024 review found a lack of evidence of effectiveness for the 12 uses it evaluated.
Zilucoplan
Also called Zilbrysq
A synthetic macrocyclic peptide complement C5 inhibitor approved by FDA as Zilbrysq for generalized myasthenia gravis in adults with acetylcholine receptor antibodies.
Cancer
Carfilzomib
Also called Kyprolis
A tetrapeptide epoxyketone proteasome inhibitor approved by FDA in 2012 as Kyprolis for relapsed or refractory multiple myeloma.
Degarelix
Also called Firmagon
A GnRH receptor antagonist peptide approved by FDA as Firmagon for the treatment of advanced prostate cancer.
Gallium Ga 68 dotatate
Also called NETSPOT, Ga-68 DOTATATE
A radioactive imaging agent built on dotatate, a cyclic eight-amino-acid peptide. FDA approved the NETSPOT kit in 2016 for PET scans that locate somatostatin receptor-positive neuroendocrine tumors.
Goserelin
Also called Zoladex
A synthetic GnRH analogue approved by FDA as Zoladex for prostate cancer, advanced breast cancer in pre- and perimenopausal women, endometriosis and endometrial thinning.
Lanreotide
Also called Lanreotide acetate, Somatuline Depot
A somatostatin analogue first approved by FDA as Somatuline Depot in 2007. The cited label covers acromegaly, certain neuroendocrine tumors and carcinoid syndrome.
Leuprolide
Also called Leuprolide acetate, Lupron, Eligard, Vobrig
A GnRH agonist FDA-approved since 1985 under several names. The cited Eligard label covers advanced prostate cancer; FDA approved Vobrig for central precocious puberty in August 2026.
Lutetium Lu 177 dotatate
Also called Lutathera
A radioactive somatostatin-analogue peptide approved by FDA as Lutathera for somatostatin receptor-positive neuroendocrine tumors of the stomach, intestines and pancreas.
Motixafortide
Also called Aphexda
A synthetic CXCR4-blocking cyclic peptide approved by FDA as Aphexda, with filgrastim, to mobilize blood stem cells for collection and transplant in multiple myeloma.
Octreotide
Also called Octreotide acetate, Sandostatin
A somatostatin analogue first approved by FDA as Sandostatin in 1988, used for acromegaly and for diarrhea and flushing caused by certain hormone-secreting tumors.
Thymosin alpha-1
Also called Thymalfasin
A 28-amino-acid thymus peptide that is not FDA-approved. FDA’s 2024 review found a lack of evidence of effectiveness for the 12 uses it evaluated.
Triptorelin
Also called Trelstar
A synthetic GnRH agonist approved by FDA as Trelstar for the treatment of advanced prostate cancer.
Muscle
Elamipretide
Also called SS-31, MTP-131, Forzinity
A mitochondria-targeting peptide that FDA granted accelerated approval as Forzinity to improve muscle strength in people with Barth syndrome weighing at least 30 kg.
Follistatin-344
Also called FS344
A form of follistatin, a natural protein, not a peptide, that blocks the muscle-limiting signal myostatin. Small gene-therapy trials have tested its gene; no FDA approval is reported.
PEG-MGF
Also called Mechano growth factor pegylated, Mechano growth factor
A pegylated form of mechano growth factor, a synthetic 24-amino-acid peptide based on the insulin-like growth factor 1 precursor. FDA has identified no human exposure data, and no FDA approval is reported.
SLU-PP-332
A small synthetic compound, not a peptide, that activates estrogen-related receptors and acted like exercise in mice. No human studies and no FDA approval are reported.
Zilucoplan
Also called Zilbrysq
A synthetic macrocyclic peptide complement C5 inhibitor approved by FDA as Zilbrysq for generalized myasthenia gravis in adults with acetylcholine receptor antibodies.
Infections
Aviptadil
Also called Zyesami
A synthetic form of vasoactive intestinal peptide, also called Zyesami, studied for COVID-19 respiratory failure. A large randomized trial found no benefit, and no FDA approval is reported in the cited sources.
Dalbavancin
Also called Dalvance
A lipoglycopeptide antibiotic approved by FDA in 2014 as Dalvance for acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, including MRSA.
Daptomycin
Also called Cubicin, Cubicin RF
A cyclic lipopeptide antibiotic approved by FDA as Cubicin and Cubicin RF for complicated skin infections and Staphylococcus aureus bloodstream infections.
Enfuvirtide
Also called Fuzeon
A synthetic peptide HIV-1 fusion inhibitor approved by FDA in 2003 as Fuzeon, which Drugs@FDA now lists as discontinued.
Thymopentin
Also called Timunox
A synthetic five-amino-acid fragment of thymopoietin, studied as an immune modulator. Randomized trials in the 1990s had mixed results, and no FDA approval is reported.
Thymosin alpha-1
Also called Thymalfasin
A 28-amino-acid thymus peptide that is not FDA-approved. FDA’s 2024 review found a lack of evidence of effectiveness for the 12 uses it evaluated.
Eyes
Thymosin beta-4
A naturally occurring human peptide, distinct from its short fragment TB-500, that has been tested in small randomized eye trials. No FDA approval is reported in the cited sources.
Not yet grouped
Peginesatide
Also called Omontys, Peginesatide acetate
A synthetic peptide-based drug for anemia in kidney disease, approved by FDA as Omontys in 2012. It was recalled in 2013 after fatal allergic reactions, and FDA withdrew its approval in 2019 at the company’s request.
Rusfertide
Also called Mimrylo
A synthetic hepcidin-mimicking peptide approved by FDA in August 2026 as Mimrylo to treat excess red blood cells in adults with polycythemia vera.
Try another name, or see which sources we cover.
Areas of study come from the cited U.S. label, registered trials, reviewed studies or FDA review for each peptide. They describe what has been studied or approved, not what anyone should use. See every peptide’s status in one table →
Looking for a list? Which peptides are FDA-approved, more common questions, and side-by-side comparisons such as BPC-157 vs TB-500.